Benzinga | Mar 2, 2021 07:20AM EST

Myriad Genetics Announces Collaboration With Intermountain Precision Genomics For Germline And Somatic Tumor Testing Services Using TheraMap Test And Sequencing Test From Illumina

SALT LAKE CITY, March 02, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a new strategic precision oncology collaboration with Intermountain Precision Genomics, a service of Intermountain Healthcare. This collaboration creates a comprehensive germline genetic testing and somatic tumor offering that combines Myriad's advanced hereditary cancer and companion diagnostic tests with Intermountain Precision Genomics' world-class laboratory services, utilizing the TheraMap(r) test--powered by the TruSight(tm) Oncology 500 (TSO 500) next-generation sequencing test from Illumina, Inc. (NASDAQ:ILMN).